loading
前日終値:
$2.815
開ける:
$2.85
24時間の取引高:
86,892
Relative Volume:
0.65
時価総額:
$138.59M
収益:
-
当期純損益:
$-41.07M
株価収益率:
-4.1364
EPS:
-0.66
ネットキャッシュフロー:
$-32.97M
1週間 パフォーマンス:
-1.09%
1か月 パフォーマンス:
+3.42%
6か月 パフォーマンス:
-15.79%
1年 パフォーマンス:
+39.49%
1日の値動き範囲:
Value
$2.71
$2.8992
1週間の範囲:
Value
$2.646
$2.8992
52週間の値動き範囲:
Value
$1.555
$4.2684

Galectin Therapeutics Inc Stock (GALT) Company Profile

Name
名前
Galectin Therapeutics Inc
Name
セクター
Healthcare (1195)
Name
電話
678-620-3186
Name
住所
4960 PEACHTREE INDUSTRIAL BOULEVARD, NORCROSS, GA
Name
職員
0
Name
Twitter
@galectingalt
Name
次回の収益日
2024-11-11
Name
最新のSEC提出書
Name
GALT's Discussions on Twitter

GALT を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
GALT 2.72 138.59M 0 -41.07M -32.97M -0.66
VRTX 450.44 115.43B 10.63B -479.80M -1.35B 13.33
REGN 748.80 82.04B 13.85B 4.65B 3.32B 35.06
ARGX 589.59 35.30B 1.86B -40.29M -1.28B -4.16
ALNY 246.35 32.04B 2.09B -332.26M 16.06M -4.14
BNTX 106.78 24.89B 3.30B -501.07M 1.03B 11.54

Galectin Therapeutics Inc Stock (GALT) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2020-08-13 繰り返されました H.C. Wainwright Buy
2019-02-13 開始されました B. Riley FBR Buy
2017-12-07 繰り返されました H.C. Wainwright Buy
2017-11-28 繰り返されました H.C. Wainwright Buy
2017-10-19 開始されました ROTH Capital Buy
2017-03-30 アップグレード H.C. Wainwright Neutral → Buy
2016-10-03 ダウングレード FBR & Co. Outperform → Mkt Perform
2016-09-29 ダウングレード H.C. Wainwright Buy → Neutral
2016-09-28 ダウングレード ROTH Capital Buy → Sell
2016-03-28 再開されました H.C. Wainwright Buy
2015-09-21 開始されました H.C. Wainwright Buy
2014-08-01 ダウングレード Aegis Capital Buy → Hold
2014-07-30 繰り返されました MLV & Co Buy
2014-07-29 繰り返されました MLV & Co Buy
2014-04-02 繰り返されました MLV & Co Buy
2014-02-10 繰り返されました Aegis Capital Buy
2014-01-09 繰り返されました Aegis Capital Buy
2013-12-03 開始されました MLV & Co Buy
2013-08-19 繰り返されました Aegis Capital Buy
すべてを表示

Galectin Therapeutics Inc (GALT) 最新ニュース

pulisher
Nov 20, 2024

StockNews.com Upgrades Galectin Therapeutics (NASDAQ:GALT) to "Hold" - MarketBeat

Nov 20, 2024
pulisher
Nov 20, 2024

Galectin Therapeutics (NASDAQ:GALT) Stock Rating Upgraded by StockNews.com - Defense World

Nov 20, 2024
pulisher
Nov 19, 2024

Non-alcoholic Steatohepatitis Treatment Market Projected to Show Strong Growth - openPR

Nov 19, 2024
pulisher
Nov 18, 2024

Galectin Therapeutics Presents Three Abstracts at the American Association for the Study of Liver Diseases (AASLD) 2024 Liver Meeting - The Manila Times

Nov 18, 2024
pulisher
Nov 18, 2024

Galectin Therapeutics Advances NAVIGATE Trial for MASH Cirrhosis Treatment, December Readout on Track | GALT Stock News - StockTitan

Nov 18, 2024
pulisher
Nov 18, 2024

HC Wainwright Analysts Decrease Earnings Estimates for GALT - MarketBeat

Nov 18, 2024
pulisher
Nov 15, 2024

Galectin Therapeutics (NASDAQ:GALT) Earns Buy Rating from HC Wainwright - MarketBeat

Nov 15, 2024
pulisher
Nov 14, 2024

Galectin Therapeutics Reports Increased Q3 Losses - TipRanks

Nov 14, 2024
pulisher
Nov 14, 2024

Galectin Therapeutics Inc (GALT) Quarterly 10-Q Report - Quartzy

Nov 14, 2024
pulisher
Nov 14, 2024

Galectin Therapeutics Advances Galectin-Based Therapeutics Pipeline - TipRanks

Nov 14, 2024
pulisher
Nov 14, 2024

Galectin Therapeutics Reports Financial Results for the Quarter Ended September 30, 2024 and Provides Business Update - The Manila Times

Nov 14, 2024
pulisher
Nov 14, 2024

electroCore to Participate at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum on November 21 - The Manila Times

Nov 14, 2024
pulisher
Nov 14, 2024

Galectin Q3 Loss Narrows to $11.2M; Key NAVIGATE Trial Results Due December | GALT Stock News - StockTitan

Nov 14, 2024
pulisher
Nov 14, 2024

Galectin Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com

Nov 14, 2024
pulisher
Nov 13, 2024

Global Dermatological Drugs Market to Cross USD 31 Billion by 2030 | DelveInsight - The Malaysian Reserve

Nov 13, 2024
pulisher
Nov 07, 2024

Galectin Therapeutics (NASDAQ: GALT): Disrupting Merck’s Cancer Dominance - Insider Financial

Nov 07, 2024
pulisher
Nov 07, 2024

Individual investors who hold 54% of Galectin Therapeutics Inc. (NASDAQ:GALT) gained 12%, insiders profited as well - Simply Wall St

Nov 07, 2024
pulisher
Nov 05, 2024

Non-Alcoholic Steatohepatitis Market to Show Remarkable Growth Trends from 2023 to 2032, DelveInsight Reports | Inventiva Pharma, Zydus Therapeutics, Novo Nordisk A/S, Viking Therapeutics, Madrigal - Barchart

Nov 05, 2024
pulisher
Nov 05, 2024

Non-Alcoholic Steatohepatitis Market to Show Remarkable - openPR

Nov 05, 2024
pulisher
Oct 29, 2024

Psoriasis Pipeline Therapeutics, Assessment, Companies, Products, Unmet Needs, Market Drivers and Barriers - Barchart

Oct 29, 2024
pulisher
Oct 29, 2024

Liver Cirrhosis Pipeline Trends 2024: Clinical Trials, Therapeutic Innovations, and Recent Developments | Astrazeneca, Bayer, Sanofi, Pfizer, Merck, Novartis - Barchart

Oct 29, 2024
pulisher
Oct 29, 2024

Liver Cirrhosis Pipeline Trends 2024: Clinical Trials, - openPR

Oct 29, 2024
pulisher
Oct 28, 2024

LIVER CIRRHOSIS MARKET TO GROW AT A SUBSTANTIAL GROWTH RATE - openPR

Oct 28, 2024
pulisher
Oct 23, 2024

Galectin therapeutics director Eldred Kary buys $1,300 in stock By Investing.com - Investing.com South Africa

Oct 23, 2024
pulisher
Oct 23, 2024

Galectin therapeutics director Eldred Kary buys $1,300 in stock - Investing.com

Oct 23, 2024
pulisher
Oct 17, 2024

Galectin therapeutics director Freeman buys $27,000 in stock By Investing.com - Investing.com Canada

Oct 17, 2024
pulisher
Oct 16, 2024

Galectin therapeutics director Freeman buys $27,000 in stock - Investing.com

Oct 16, 2024
pulisher
Oct 16, 2024

Galectin Therapeutics Inc. (NASDAQ:GALT) Director Purchases $13,500.00 in Stock - MarketBeat

Oct 16, 2024
pulisher
Oct 15, 2024

Galectin Therapeutics (NASDAQ:GALT) Upgraded to Hold at StockNews.com - Defense World

Oct 15, 2024
pulisher
Oct 15, 2024

Application Monitoring Suites Market Size and Industry Overview - News in Assen

Oct 15, 2024
pulisher
Oct 15, 2024

Galectin Therapeutics Announces Acceptance of Three Abstracts for the American Association for the Study of Liver Diseases (AASLD) 2024 Liver Meeting - The Manila Times

Oct 15, 2024
pulisher
Oct 15, 2024

Non Alcoholic Fatty Liver Disease (NAFLD) Clinical Trials 2024: - openPR

Oct 15, 2024
pulisher
Oct 15, 2024

Non Alcoholic Fatty Liver Disease (NAFLD) Clinical Trials 2024: EMA, PDMA, FDA Approvals, Medication, Statistics, Drugs, Mechanism of Action, Route of Administration, and Companies by DelveInsight - The Globe and Mail

Oct 15, 2024
pulisher
Oct 15, 2024

Microsoft Corp (MSFT-Q) QuotePress Release - The Globe and Mail

Oct 15, 2024
pulisher
Oct 15, 2024

Nonalcoholic Steatohepatitis Treatment Market Size, Innovations Driving Market Evolution (2024-2034) - IndiaPolitics.com

Oct 15, 2024
pulisher
Oct 14, 2024

Marshall Wace LLP Buys New Shares in Security National Financial Co. (NASDAQ:SNFCA) - Defense World

Oct 14, 2024
pulisher
Oct 14, 2024

Marshall Wace LLP Cuts Stock Holdings in ARC Document Solutions, Inc. (NYSE:ARC) - Defense World

Oct 14, 2024
pulisher
Oct 14, 2024

AXT, Inc. (NASDAQ:AXTI) Stock Holdings Trimmed by Marshall Wace LLP - Defense World

Oct 14, 2024
pulisher
Oct 14, 2024

The Manufacturers Life Insurance Company Has $951,000 Stock Holdings in Huntsman Co. (NYSE:HUN) - Defense World

Oct 14, 2024
pulisher
Oct 14, 2024

Marshall Wace LLP Buys New Holdings in Hanesbrands Inc. (NYSE:HBI) - Defense World

Oct 14, 2024
pulisher
Oct 06, 2024

Research Analysts’ Updated EPS Estimates for October 6th (APVO, CNP, FDX, FLNT, FRD, GALT, HOPE, KBR, LSXMK, NVGS) - Defense World

Oct 06, 2024
pulisher
Oct 06, 2024

Galectin Therapeutics (NASDAQ:GALT) Rating Increased to Hold at StockNews.com - Defense World

Oct 06, 2024
pulisher
Oct 06, 2024

Galectin Therapeutics (NASDAQ:GALT) Upgraded at StockNews.com - MarketBeat

Oct 06, 2024
pulisher
Oct 04, 2024

Global Non-Alcoholic Steatohepatitis Treatment Market Overview And Statistics For 2024-2033 - EIN News

Oct 04, 2024
pulisher
Oct 02, 2024

Ipsen's IQIRVO Approval Has Intensified the Primary Biliary Cholangitis Market Space | DelveInsight - The Malaysian Reserve

Oct 02, 2024
pulisher
Oct 02, 2024

Rhumbline Advisers Purchases New Holdings in Galectin Therapeutics Inc. (NASDAQ:GALT) - Defense World

Oct 02, 2024
pulisher
Sep 30, 2024

Galectin Therapeutics to Participate in the H.C. Wainwright MASH Conference - The Manila Times

Sep 30, 2024
pulisher
Sep 30, 2024

Annovis Files Three New Patents for Combination Therapies Involving Buntanetap, Trulicity, and Viagra - The Manila Times

Sep 30, 2024
pulisher
Sep 29, 2024

Galectin Therapeutics (FRA:PHPN) Interest Expense : €-3.71 Mil (TTM As of Jun. 2024) - GuruFocus.com

Sep 29, 2024
pulisher
Sep 29, 2024

Galectin Therapeutics (FRA:PHPN) Change In Prepaid Assets : €-0.16 Mil (TTM As of Jun. 2024) - GuruFocus.com

Sep 29, 2024
pulisher
Sep 28, 2024

StockNews.com Lowers Galectin Therapeutics (NASDAQ:GALT) to Sell - MarketBeat

Sep 28, 2024

Galectin Therapeutics Inc (GALT) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
$18.98
price up icon 1.80%
$70.68
price down icon 0.42%
$38.38
price up icon 3.49%
$369.83
price up icon 1.48%
$196.58
price up icon 0.88%
$102.64
price up icon 0.27%
大文字化:     |  ボリューム (24 時間):